{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-353308","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2026-08-17T12:50:21+00:00","discovered_at":"2026-08-17T12:55:01.693198+00:00","generated_at":"2026-08-17T12:55:34.785825+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"EyePoint DURAVYU LUGANO trial misses primary endpoint; secondary endpoints strong","bullets":["Primary endpoint not met in full dataset; ad hoc analysis excluding 4% asymmetric cohort (9/211) showed non-inferiority to aflibercept (p=0.0096).","42% reduction in treatment burden vs aflibercept (p<0.0001); 76% supplement-free to Week 32, 54% to Week 56.","79% of DURAVYU patients received 0 or 1 supplement up to Week 56; supplement-free BCVA non-inferior (p=0.0035).","LUCIA topline expected Q4 2026; NDA filing planned 1H 2027; DME trials COMO/CAPRI topline Q4 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-353308","json":"https://secwatch.observer/filing/0001193125-26-353308.json","markdown":"https://secwatch.observer/filing/0001193125-26-353308.md","text":"https://secwatch.observer/filing/0001193125-26-353308.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/0001193125-26-353308-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-20260817.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-17T12:55:34.785825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}